Navigation Links
Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week

CARSON CITY, Nev., April 9, 2012 /PRNewswire/ -- Rapid Fire Marketing (Pink Sheets: RFMK) announced today that the Vapor Inhaler's CannaCig model has passed all tests, including actual trials done by medical marijuana patients over the weekend. Additionally, pre-orders for the Vapor Inhaler's CannaCig model have been coming in through and the distributor side of Rapid Fire Marketing's website. A substantial marketing effort has been underway through the weekend, and will be stepped up this week and beyond, to build interest and awareness of the CannaCig. Marketing includes viral campaigns, street marketing and product posters which include one already visible on Hollywood Blvd. in Los Angeles which has substantial traffic. The CannaCig will be available at Otherside Health Management and Tabu Smoke Shops starting today. Otherside expects to sell out of our first trial run before the week's end and Tabu is already requesting more units. The Vapor Inhaler CannaCig model will be distributed nationwide after the next order arrives.

"We are ready to move forward now with full production of the Vapor Inhaler's first model which we named the CannaCig. There are specific actions being taken in anticipation of our next order's delivery. This week we will set up our distributor program including following up on solid leads that we want to act on quickly. We have talked to several distributors that want the CannaCig as soon as possible. Next, we will set up our online store and an affiliate program for websites to sell the unit, minus the active ingredient of course," said Tom Allinder, CEO of Rapid Fire Marketing.

The clear success of the CannaCig is prompting Rapid Fire Marketing to order a second round of production. The size of the production is set to be 500 units but could grow depending on the final count of pre-orders and interested vendors. Production cost will now be reduced to $30.00 per unit while the pricing structure will remain the same, with a retail price of $99.95 per empty unit and $120.00 with the active agent.

"The effort to transform this company into a structured entity and viable brand name is under way. The business plan is almost complete. I am being persistent with the DTCC to discover a reason for the chill and have it removed. Obviously, we need to achieve larger production runs but that can only be done through the growth financing I have been speaking of over the last couple months. That continues to be a big focus of mine and will be until we have a deal in place that enables us to do large production runs, introduce our new products and hire more staff," said Allinder.

"I would like to send a big thanks to Judah Neiditch at Otherside Health Management for all the hard work. None of this could have been possible without his tireless dedication in bringing this CannaCig project to the market. We sure had more than our fair share of obstacles but Judah worked through them all. I am so happy to be working with such a dedicated and resourceful individual," Allinder concluded.

"Wow! What a weekend it has been. We have had quite a few medical marijuana patients come through Otherside over the testing period and they all agree that this is the best unit on the market. Many who used the Vapor Inhaler during our launch event requested to take a unit home and committed to return today and get one of their own. I personally use it everywhere I can, with who ever will try it, and the response is always the same: 'Where can I get one?' These are going to sell out fast. My drive now is to ensure everyone, everywhere, can use this great device and will not rest until it has reached every continent on the planet," said Judah Neiditch of Otherside Health Management.

Safe Harbor:

From time to time, the Company may issue news releases that contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statement provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward-looking statements." "Forward-looking statements" are based upon expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those anticipated.

SOURCE Rapid Fire Marketing
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol
3. Launches Pelvic Health Program Model to Help Hospitals Rapidly Expand Key Services
4. FUJIFILM Medical Systems U.S.A. Adds FUJINON Endoscopy to Its Rapidly Expanding Portfolio
5. Abaxis Animal Health Announces the Addition of a Feline Heartworm Application to the Rapid Diagnostics Product Line
6. Olympus Introduces New Peracetic Acid Solution for Rapid High-Level Disinfection
7. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
8. OrbusNeichs Genous™ Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation
9. New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
10. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
11. Rapid Fire Marketing: Medical Cannabis Management Signs Agreement with Second Non-Profit
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
Breaking Medicine Technology:
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... most successful and prominent nonprofit healthcare organizations in the country. They have overseen ... various organizations, and helped advance the healthcare industry as a whole through their ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical ... professionals and offered by healthcare staffing agency Aureus Medical Group . ... of October 2015 among those searching for healthcare jobs through the company’s website, ...
Breaking Medicine News(10 mins):